Clinical impact of induction treatment modalities and optimal timing of radiotherapy for the treatment of limited-stage NK/T cell lymphoma

Joon Ho Moon, Bo Hee Lee, Jeong A. Kim, Yoo Jin Lee, Yee Soo Chae, Ho Young Yhim, Jae Yong Kwak, Young Rok Do, Yong Park, Moo Kon Song, Ho Jin Shin, Therasa Kim, Je jung Lee, Deok Hwan Yang

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

This study retrospectively investigated the optimal timing of radiotherapy (RT) in patients with limited-stage extranodal NK/T-cell lymphoma (ENTKL). Among 158 patients with newly diagnosed stage I/II ENKTL, 61 patients were treated with sequential chemotherapy followed by radiotherapy (SCRT), 55 with concurrent chemoradiotherapy followed by non-anthracycline-based chemotherapy (CCRT/CT), and 42 with chemotherapy (CT) only. The 5-year overall survival (OS) rate did not differ between SCRT (77.7 ± 5.5%) and CCRT/CT (68.9 ± 6.8%; p = 0.234). In the SCRT group, 18 patients (29.5%) relapsed within the RT field and 6 (9.8%) at systemic sites, while in the CCRT/CT group, 9 patients (16.4%) relapsed at the primary site and 14 (25.5%) at systemic sites. The 5-year cumulative incidence of relapse (CIR) at primary sites was 26.3% and 19.2% after SCRT and CCRT/CT (p = 0.308), while the 5-year CIR of systemic sites was 8.7% and 26.5% after SCRT and CCRT/CT, respectively (p = 0.010). In the multivariate analysis, NK/T-cell Prognostic Index score and CR achievement were the most important prognostic factors for survival. Although up-front RT had limitations in systemic disease control and was associated with an increased risk of systemic relapse during RT compared to SCRT, timing of RT did not significantly affect survival outcomes.

Original languageEnglish
Pages (from-to)80-87
Number of pages8
JournalLeukemia Research
Volume49
DOIs
Publication statusPublished - 2016 Oct 1

Keywords

  • Chemotherapy
  • Extranodal NK/T cell lymphoma
  • Radiotherapy
  • Relapse

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Clinical impact of induction treatment modalities and optimal timing of radiotherapy for the treatment of limited-stage NK/T cell lymphoma'. Together they form a unique fingerprint.

  • Cite this

    Moon, J. H., Lee, B. H., Kim, J. A., Lee, Y. J., Chae, Y. S., Yhim, H. Y., Kwak, J. Y., Do, Y. R., Park, Y., Song, M. K., Shin, H. J., Kim, T., Lee, J. J., & Yang, D. H. (2016). Clinical impact of induction treatment modalities and optimal timing of radiotherapy for the treatment of limited-stage NK/T cell lymphoma. Leukemia Research, 49, 80-87. https://doi.org/10.1016/j.leukres.2016.08.015